Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Beijing Biostar Pharmaceuticals Co 9-Day RSI Related Terms
HKSE:02563 vs VRTX, REGN, MRNA: 9-Day RSI Comparison
For the Biotechnology subindustry, Beijing Biostar Pharmaceuticals Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Biostar Pharmaceuticals Co 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Biostar Pharmaceuticals Co's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Beijing Biostar Pharmaceuticals Co's 9-Day RSI falls into.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a 9-Day RSI of 65.45 as of Sep. 01, 2026. According to the industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #1272 out of 1421 companies in the Biotechnology industry, placing it in the top 89.5%.
Is Beijing Biostar Pharmaceuticals Co's 9-Day RSI too high?
Beijing Biostar Pharmaceuticals Co's current 9-Day RSI is 65.45. The Biotechnology industry median 9-Day RSI is 46.83. Beijing Biostar Pharmaceuticals Co's value of 65.45 is 39.8% above this industry median. Based on the distribution chart, Beijing Biostar Pharmaceuticals Co ranks #1272 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Biostar Pharmaceuticals Co ranks #1272 out of 1421 companies for 9-Day RSI. This places Beijing Biostar Pharmaceuticals Co in the lower half of its industry. The industry median 9-Day RSI is 46.83. Beijing Biostar Pharmaceuticals Co's value of 65.45 is 39.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 46.83, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Biostar Pharmaceuticals Co's current 9-Day RSI of 65.45 is 39.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 46.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Biostar Pharmaceuticals Co's current 9-Day RSI is 65.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current 9-Day RSI of 65.45. The current 9-Day RSI is 65.45 and 39.8% above the Biotechnology industry median of 46.83. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current 9-Day RSI is 65.45 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score
Get the complete analysis for HKSE:02563
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02563 has been successfully added to your 
